AstraZeneca to invest $2.5 billion in new global strategic R&D centre in China
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
These appointments align with the group’s philosophy of having a strong and independent board with exceptional industry experts, ensuring strategic guidance and effective governance
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
The programme will take place on the 2nd Sunday of every month
Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies
Encourages working women to practice self-care
Subscribe To Our Newsletter & Stay Updated